Esperion Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on bringing new medicines to patients that address unmet medical needs.
The company has developed and is commercializing U.S. Food and Drug Administration, or FDA, ap…
Analysis
Middle-of-the-road
Esperion Therapeutics, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction. Worth noting: the cash the business generates has lagged behind what the income statement shows.
Valuation data is not available for this company.
Growth is moderate; the safety picture is fragile. The company scores 7/20 on our value-creation score: creating some value. Analyst sentiment is cautious.
Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Jan 20231
88
2023202420252026
All-time high
88
Jun 2026
All-time low
1
Jan 2023
Average rank
50
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
100
76
82
38
Price/Earnings
5
7
100
14
Price/Book
76
92
100
92
Dividend Yield
1
1
1
1
Value (overall)
76
80
88
55
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.